정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 639 | Recruiting | Safety and Immunogenicity of a SARS CoV 2 Multivalent RNA Vaccine in Healthy Participants | SARS (Disease) | Biological: BNT162b2 Biological: BNT162b2 (B.1.1.7 + B.1.617.2) Biological: BNT162b2 (B.1.1.7) Biological: BNT162b2 (B.1.617.2) |
Phase 2 | BioNTech SE | INDUSTRY | 1245 | All | 18 Years ~ 85 Years | California Research Foundation, San Diego, California, United States Clinical Research Consulting, Llc, Milford, Connecticut, United States Amici Clinical Research, Raritan, New Jersey, United States Rochester Clinical Research, Rochester, New York, United States Aventiv Research Inc., Columbus, Ohio, United States North Texas Infectious Diseases Consultants, Dallas, Texas, United States Clinical Trials of Texas Inc., San Antonio, Texas, United States Diagnostics Research Group, San Antonio, Texas, United States |
| 638 | Active, not recruiting | Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19) | COVID-19 (Healthy Volunteers) | Biological: NBP2001 adjuvanted with alum (RBD 30μg/dose) Biological: NBP2001 adjuvanted with alum (RBD 50μg/dose) Other: Normal Saline |
Phase 1 | SK Bioscience Co., Ltd. | INDUSTRY | 50 | All | 19 Years ~ 55 Years | Seoul National University Bundang Hospital, Seongnam-si, Bundang, Korea, Republic of Seoul National University Hospital, Seoul, Korea, Republic of |
| 637 | Active, not recruiting | Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study) | Healthy Volunteers | Biological: AdCOVID Other: Placebo |
Phase 1 | Altimmune, Inc. | INDUSTRY | 92 | All | 18 Years ~ 55 Years | Optimal Research, Melbourne, Florida, United States Optimal Research, Peoria, Illinois, United States Optimal Research, Rockville, Maryland, United States Optimal Research, Austin, Texas, United States Clinical Trials of Texas, San Antonio, Texas, United States |
| 636 | Recruiting | Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults | Covid19 | Biological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops Biological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops Biological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops Biological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal Drops Biological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Spray |
Phase 1 | Meissa Vaccines, Inc. | INDUSTRY | 130 | All | 18 Years ~ 69 Years | Johnson County Clin-Trials, Lenexa, Kansas, United States |
| 635 | Active, not recruiting | Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19 | SARS-CoV Infection | Biological: BBV154 Vaccine Biological: Placebo |
Phase 1 | Bharat Biotech International Limited | INDUSTRY | 175 | All | 18 Years ~ 60 Years | AIIMS,Patna, Patna, Bihar, India Apollo Hospitals,Chennai, Chennai, Tamil Nadu, India St.Theresa Hospital, Hyderabad, Hyderabad, India Gillurkar Multispeciality Hospital,Nagpur, Nagpur, India |
| 634 | Recruiting | Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine | Influenza | Biological: BPL-1357 Other: IM Placebo Other: IN Placebo |
Phase 1 | National Institute of Allergy and Infectious Diseases (NIAID) | NIH | 45 | All | 18 Years ~ 55 Years | National Institutes of Health Clinical Center, Bethesda, Maryland, United States |
| 633 | Recruiting | Safety and Immunogenicity of COVID-19 Vaccination in Patients With Cancer | Vaccine | Biological: Coronavirus vaccine | Not Applicable | Beijing 302 Hospital | OTHER | 300 | All | 18 Years | The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China |